Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See
full details
.
I Agree
×
Join today and have your say! It’s FREE!
Join Now
Sign In
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.
Join Today
or
Sign in with existing account
Privacy Policy
|
Disclaimer
Sign In
Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Remember me
Forgot Password?
Sign In
or
Sign Up
Privacy Policy
|
Disclaimer
Please Try Again
{{ error }}
Send my password
Submit
Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.
Become a member today, It's free!
We will not release or resell your information to third parties without your permission.
Linking with Facebook:
Stockhouse membership requires an email address which must be shared by Facebook.
By default, joining or signing in using your Facebook account will work and the email address will be shared by Facebook automatically.
If you change your Facebook permissions to restrict Stockhouse from receiving your email while joining or signing in to Stockhouse then it will fail.
Please do not modify the permission settings during sign-in.
Sign in with Facebook
Return to Signup Options
Home
Community
Bullboards
Blogs
Groups
Messages
Markets
Stocks
TSX
TSXV
CSE
Cboe Canada
NASDAQ
NYSE
NYSE American
Cryptocurrency
Currencies
Market Movers
Bonds
News
Featured News
Trending News
Canadian Press Releases
US Press Releases
Video
Editorial
Thematic Insights
Independent Reports
Interviews
Buzz on the Bullboards
Portfolio
Watchlist
Portfolio
Showcase Companies
DealRoom
Quote
|
Bullboard
|
News
|
Opinion
|
Profile
|
Peers
|
Filings
|
Financials
|
Options
|
Price History
|
Ratios
|
Ownership
|
Insiders
|
Valuation
Bullboard - Stock Discussion Forum
Antibe Therapeutics Inc(Pre-Merger)
ATBPF
Healthcare
Antibe Therapeutics Inc. is a clinical-stage biotechnology company. The Company is leveraging its hydrogen sulfide (H2S) platform to develop therapies to target inflammation arising from a range of medical conditions. The Company’s pipeline includes assets that seek to overcome the gastrointestinal ulcers and bleeding associated with nonsteroidal anti-inflammatory drugs (NSAIDs). Its lead drug,...
otenaproxesul, is in clinical development as an alternative to opioids and NSAIDs for acute pain. Its second pipeline drug, ATB-352, is being developed for a specialized pain indication. The Company also focuses on inflammatory bowel disease (IBD). Otenaproxesul combines a moiety that releases hydrogen sulfide with naproxen, a non-steroidal, anti-inflammatory drug. ATB-352 is an H2S-releasing derivative of ketoprofen, a potent NSAID commonly prescribed for acute pain. Its IBD candidates are being designed to maintain the efficacy, safety, and pharmacokinetic properties of ATB-429.
see more
Join the community and start posting on the bullboards today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Create a portfolio watchlist today. It's free.
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
Add To Watchlist
Bullboard (GREY:ATBPF)
New Post
View:
Posts & Comments
Threaded Posts
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 15, 2023 12:37am
RE:RE:RE:RE:IBD News - Q3?
It isn't about hitting or missing timelines - it's about choosing "when" to release. Lets wait for A before we do B.
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 14, 2023 12:44pm
Also the PK/PD otena study
could be out as early as oct/1, but likely it will be released closer to dec/31 because that is just how these guys roll haha The following summarizes the Company’s estimated timeline
...more
Level Up Your Trading with BMO InvestorLine’s Enhanced Features
posted Nov 24, 2024 9:00am by
Bank of Montreal
-
|
Features like Multi-Leg Orders, Options Screener, and Strategy Builder will be particularly exciting for traders. They have been designed to be intuitive and user-friendly, regardless of your experience level. Whether you’re a seasoned pro or just starting out, you’ll find these tools easy to navigate and adapt to your investing style. ...read more
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Sep 14, 2023 12:32pm
RE:RE:RE:IBD News - Q3?
Q3 still has some daylight but a delay to Q4 (or later...?) at this point chips away at the remaining confidence I had in the Antibe team. WTH are we to think if they are unable to meet
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 14, 2023 9:05am
Announcement before end of september?
but they have been known to have delays, also they inserted the word "expected" lol Selected lead and back-up candidates for a family of new anti-inflammatory
...more
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Sep 13, 2023 5:59pm
RE:RE:IBD News - Q3?
Not IBD but a new molecule was planned to be introduced in Q3. Don't expect it until Q4.
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Sep 13, 2023 12:35pm
RE:IBD News - Q3?
They had opportunity to change the timeline with the July update...that made me think they must be confident with only 2months remaining in the Quarter.
(218)
•••
baggerx99
X
View Profile
View Bullboard History
Post by
baggerx99
on Sep 13, 2023 12:25pm
IBD News - Q3?
End of Q3 is nearing?
(0)
•••
PressRelease
X
View Profile
View Bullboard History
Post by
PressRelease
on Sep 08, 2023 5:01pm
New Press Release - Antibe Announces Results of 2023 Annual Meeting
Antibe Therapeutics Inc. (TSX: ATE, OTCQX: ATBPF), a clinical-stage company leveraging its hydrogen sulfide platform to develop next-generation therapies to target inflammation, is pleased to announce the results of its annual meeting of shareholders (the “Meeting”) held earlier today. All...
read article.
(26)
•••
Pronorvista
X
View Profile
View Bullboard History
Post by
Pronorvista
on Sep 05, 2023 8:33pm
Ate
For once for a long time it seems to take care of the secondary market
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Sep 05, 2023 7:54pm
RE:Raise your hand🖐
Time and testing will tell. I don't quite see the blowing sunshine angle though? IMO there are exciting times ahead...
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 05, 2023 3:52pm
Raise your hand🖐
if you think antibe has made a breakthrough, or do you think they are just blowing smoke up are buts. by the performance in the stock price i would have to say investors are skeptical, also no insider
...more
(1202)
•••
Duster340
X
View Profile
View Bullboard History
Post by
Duster340
on Sep 05, 2023 3:34pm
Video from aug/21
dan thinks they cracked the code? https://youtu.be/oPUSPUIE5Uw
(128)
•••
MrMugsy
X
View Profile
View Bullboard History
Comment by
MrMugsy
on Aug 30, 2023 6:03pm
RE:Discovery Program...
I am also curious about the discovery program. Sure hope it's around Ketorolac. That would explain a lot of things right now. Regardless - to your point, likely makes no difference to
...more
(55)
•••
Harper75
X
View Profile
View Bullboard History
Comment by
Harper75
on Aug 30, 2023 4:17pm
RE:Discovery Program...
Managed to spell hopeful incorrectly TWICE in the same post - can't even blame 4:20
(55)
•••
Harper75
X
View Profile
View Bullboard History
Post by
Harper75
on Aug 30, 2023 4:05pm
Discovery Program...
I'm anxiously awaiting the upcoming (Q3/2023) announcement on the Discovery Program but I'm tempering my expectation of ANY market reaction considering the lack of market interest at the
...more
Prev
...
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
...
Next
Thank You
Your Report has been submitted.
Report Abusive Content
×
Close
Sign up to get access
You are already a member! Please enter your password to sign in.
Remember me
Forgot password?
Back
Submit
By providing my email, I consent to receiving messages from Stockhouse.
The Market Update
{{currentVideo.title}}
{{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >
A daily snapshot of everything
from market open to close.
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}
{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >